MAP2K2 and lung carcinoma: We then extended our study of this combination therapy approach to a series of relatively insensitive KRASG12C mutant lung cancer PDX models with various co-existent genetic lesions (mutant TP53, STK11/LKB1, KEAP1, MEK2) (Fig. 3c).